BioWorld

July 14, 2009

View Archived Issues

Tarceva Survival Data Intensify Lung Cancer Maintenance Battle

It's been barely a week since Eli Lilly and Co.'s chemotherapy drug Alimta (pemetrexed) received the first-ever FDA approval in the maintenance treatment of lung cancer, and already the competition is closing in. (BioWorld Today) Read More

Antiplatelet Space Growing, Plavix Still Strong - for Now

Read More

Mixed News on H1N1 Emerges from WHO and Nature Study

Read More

NewCo News: Cardioxyl's Nitroxyl Donor Drug Starts Testing in Heart Failure

Read More

HHS Piles on Swine Flu Money: $884M More for H1N1 Vaccine

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More